Skip to Main Content

Paper Details

Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo.
BMJ Open
9
2022
Author NameAffiliation
Daniel G BauschLondon School of Hygiene & Tropical Medicine
Daniel G Bausch
Jean-Jacques Muyembe-TamfumL'Institut National de Recherche Biomedicale
  • 1 - 3

Datasets

Release 1.2